natgillin/translations-raw huggingface dataset:
Docetaxel Zentiva er et antineoplastisk stof, og ligesom andre potentielle toksiske stoffer skal det behandles med forsigtighed ved håndtering og tilberedning af Docetaxel Zentiva-opløsningerne.
Docetaxel Zentiva is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Docetaxel Zentiva solutions.
Må ikke opbevares ved temperaturer over 25 ºC.
SPECIAL STORAGE CONDITIONS Do not store above 25°C.
• Ved behandling af prostatakræft kan Docetaxel Zentiva indgives i kombination med prednison eller prednisolon.
- For the treatment of prostate cancer, Docetaxel Zentiva is administered in combination with prednisone or prednisolone.
Den nødvendige mængde Docetaxel Zentiva koncentrat til infusionsvæske, opløsning, skal via en enkelt injektion (et skud) injiceres i en 250 ml infusionspose eller -flaske indeholdende enten en 5 % glucoseinfusionsvæske eller en 0,9 % natriumchloridinfusionsvæske.
The required volume of Docetaxel Zentiva concentrate for solution for infusion must be injected via a single injection (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion.
måneder.
2 years
Docetaxel Zentiva i kombination med cisplatin og 5-fluoruracil er indiceret til indledende behandling af patienter med inoperable, lokale, fremskredne skællede celle-carcinoma i hoved og hals.
Docetaxel Zentiva in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Hvis Docetaxel Zentiva infusionskoncentrat eller infusionsvæske skulle komme på huden, så vask omgående og grundigt med sæbe og vand.
If Docetaxel Zentiva concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water.
Feber (G3: 1%) Oral candidiasis Hypokalcæmi (G3: 0%) Hypofosfatæmi (G3-4: 1%) Hypokaliæmi (G3: 0%)
Oral candidiasis Hypocalcaemia (G3: 0%) Hypophosphataemia (G3-4: 1%) Hypokalaemia (G3: 0%)
• Ved behandling af lungekræft kan Docetaxel Zentiva enten indgives alene eller i kombination med cisplatin.
- For the treatment of lung cancer, Docetaxel Zentiva could be administered either alone or in combination with cisplatin.
Docetaxel Zentiva i kombination med cisplatin og 5-fluoruracil er indiceret til behandling af patienter med metastatisk gastrisk adenokarcinom, inklusive adenokarcinom i den gastrooesophageale forbindelse, som ikke tidligere har fået kemoterapi mod metastatisk sygdom.
Docetaxel Zentiva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
445 patienter med KPS  70 blev behandlet med enten docetaxel (T) (75 mg/m2 på dag 1) i kombination med cisplatin (C) (75 mg/m på dag 1) og 5-fluoruracil (F) (750 mg/m pr. dag i 5 dage)
A total of 445 patients with KPS > 70 were treated with either docetaxel (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and 5-fluorouracil (F) (750 mg/m2 per day for 5 days) or cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2 per day for 5 days).
Alopeci (G3: 3%) Negleforandringer (G3: 1%)
Alopecia (G3: 3%)a Nail changes (G3: 1%)
• Docetaxel 30 mg/m administreret ugentlig i de første 5 uger i en 6 ugers behandlingsrunde i 5
• Docetaxel 30 mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.
3) i mere end 7 dage i løbet af en docetaxelbehandling, anbefales det at reducere dosis i de efterfølgende cyklusser eller at tage passende symptomatiske forholdsregler (se pkt.
In the case of severe neutropenia (< 500 cells/mm3 for seven days or more) during a course of docetaxel therapy, a reduction in dose for subsequent courses of therapy or the use of appropriate symptomatic measures are recommended (see section 4.2).
• Mitoxantrone 12 mg/m hver 3. uge i 10 behandlingsrunder.
• Mitoxantrone 12 mg/m2 every 3 weeks for 10 cycles.
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket.
- If you get any side effects, talk to your doctor, hospital pharmacist or nurse.
• Ved behandling af tidlig brystkræft med eller uden lymfeknuder, kan Docetaxel Zentiva anvendes i kombination med doxorubicin eller cyclophosphamid.
- For the treatment of early breast cancer with or without lymph node involvement, Docetaxel Zentiva could be administered in combination with doxorubicin and cyclophosphamide.
Hvis Docetaxel Zentiva infusionskoncentrat eller infusionsvæske skulle komme i kontakt med slimhinderne, så vask omgående og grundigt med vand.
If Docetaxel Zentiva concentrate or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water.
Docetaxel Zentiva i kombination med doxorubicin og cyclophosphamid: Adjuverende behandling
Docetaxel Zentiva in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Docetaxel Zentiva i kombination med doxorubicin
Docetaxel Zentiva in combination with doxorubicin
• Standarpleje + docetaxel 75 mg/m², administreret hver 3. uge i 6 perioder
• Standard of care + docetaxel 75 mg/m², administered every 3 weeks for 6 cycles
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Docetaxel Zentiva i alle undergrupper af den pædiatriske population ved brystkræft, ikkesmåcellet lungekræft, prostatakræft, gastrisk adenokarcinom og hoved- og halskræft med undtagelse af type II og type III lavt differentieret nasofaryngealt karcinom (se pkt.
The European Medicines Agency has waived the obligation to submit the results of studies with Docetaxel Zentiva in all subsets of the paediatric population in breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma (see section 4.2 for information on paediatric use).
Hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion blev reduceret hos patienter der fik primær G-CSF-profylakse (se pkt.
The incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis (see section 4.8).
I kombination med capecitabin er den anbefalede Docetaxel Zentiva-dosis 75 mg/m2 hver 3. uge kombineret med capecitabin 1250 mg/m to gange daglig (indenfor 30 minutter efter et måltid) i 2 uger efterfulgt af en uges pause.
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m2 every three weeks, combined with capecitabine at 1250 mg/m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period.
Docetaxel Zentiva i kombination med prednison eller prednisolon er indiceret til behandling af patienter med metastatisk kastrationsresistent prostatakræft.
Docetaxel Zentiva in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
Patienter i docetaxel-armen fik docetaxel (T) 75 mg/m efterfulgt af cisplatin (P) 75 mg/m efterfulgt af 5-fluoruracil 750 mg/m daglig som en kontinuerlig infusion i 5 dage.
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by 5-fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days.
• Induktions kemoterapi efterfulgt af strålebehandling (TAX 323) Sikkerheden og effekten af docetaxel i den indledende behandling af patienter med pladecellecarcinom i hovedet og halsen (SCCHN) blev evalueret i et fase III, multicenter, åbent, randomiseret studie (TAX323).
• Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multi-centre, open-label, randomised study (TAX323).
Forsigtighedsregler ved behandling af kastrationsresistent prostatakræft Ud af 333 patienter behandlet med docetaxel hver tredje uge i et prostatakræftstudium (TAX 327), var 209 patienter 65 år eller derover og 68 patienter var ældre end 75 år.
Cautions for use in castration-resistant prostate cancer Of the 333 patients treated with docetaxel every three weeks in a prostate cancer study (TAX 327), 209 patients were 65 years of age or greater and 68 patients were older than 75 years.
Som ved alle andre parenterale lægemidler skal Docetaxel Zentiva infusionsvæske kontrolleres visuelt for uklarheder, og opløsninger med udfældning skal kasseres.
As with all parenteral products, Docetaxel Zentiva infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.
I dette studie viste AT-armen en hyppigere forekomst af alvorlig neutropeni (90 % versus 68,6 %), febril neutropeni (33,3 % versus 10 %), infektion (8 % versus 2,4 %), diarré (7,5 % versus 1,4 %), asteni (8,5 % versus 2,4 %) og smerter ((2,4 % versus 0 %) end AC-armen.
In this study, AT arm showed a higher incidence of severe neutropenia (90% versus 68.6%), febrile neutropenia (33.3% versus 10%), infection (8% versus 2.4%), diarrhoea (7.5% versus 1.4%), asthenia (8.5% versus 2.4%), and pain (2.8% versus 0%) than AC arm. On the other hand, AC arm showed a higher incidence of severe anaemia (15.8% versus 8.5%) than AT arm, and, in addition, a higher incidence of severe cardiac toxicity: congestive heart failure (3.8% versus 2.8%), absolute LVEF decrease  20% (13.1% versus 6.1%), absolute LVEF decrease  30% (6.2% versus 1.1%).
Med docetaxel er der rapporteret tilfælde af kutan lupus erythematosus, bulløst udslæt såsom erythema multiforme og alvorlige kutane bivirkninger såsom Stevens-Johnson syndrom, toksisk epidermal nekrolyse og akut generaliseret eksantematøs pustulose.
Cases of cutaneous lupus erythematosus, bullous eruptions such as erythema multiforme and severe cutaneous adverse reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported with docetaxel.
Dato for første markedsføringstilladelse: 20. april 2007 Dato for seneste fornyelse: 20. april 2012
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 April 2007
På grund af risiko for skadelige påvirkninger af barnet skal amning derfor ophøre under behandling med docetaxel.
Consequently, because of the potential for adverse reactions in nursing infants, breast-feeding must be discontinued for the duration of docetaxel therapy.
Docetaxel Zentiva i kombination med capecitabin
Docetaxel Zentiva in combination with capecitabine
Sanofi-Aventis Deutschland GmbH
Manufacturer(s) Sanofi-Aventis Deutschland GmbH Industriepark Höchst
Perifer sensorisk neuropati (≥G3: 2%)
Peripheral sensory neuropathy (≥G3: 2%)a
Der skal tages hensyn hertil ved behandling af gravide og ammende kvinder, børn samt patienter i højrisikogrupper såsom patienter med leversygdom, eller epilepsi.
To be taken into account in pregnant or breast-feeding women, in children and high-risk groups such as patients with liver disease, or epilepsy.
I studiet GEICAM 9805 forekom perifer sensorisk neuropati under behandlingen og fortsatte ind i opfølgningsperioden hos 10 patienter (1,9 %) i TAC-armen og 4 patienter (0,8 %) i FACarmen.Ved afslutningen af opfølgningsperioden (median opfølgningstid på 10 år og 5 måneder) blev det observeret, at perifer sensorisk neuropati fortsatte hos 3 patienter (0,6 %) i TAC-armen og hos 1 patient (0,2 %) i FAC-armen.
In GEICAM 9805 study peripheral sensory neuropathy that started during the treatment period persisted into the follow-up period in 10 patients (1.9%) in TAC arm and 4 patients (0.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), peripheral sensory neuropathy was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Tabel over bivirkninger i højrisiko lokalt avanceret eller metastatisk hormonfølsom prostatakræft med DOCETAXEL 75 mg/m² i kombination med prednison eller prednisolon og androgen deprivationsbehandling (STAMPEDE studie).
Tabulated list of adverse reactions in high-risk locally advanced or metastatic hormone-sensitive prostate cancer for DOCETAXEL 75 mg/m² in combination with prednisone or prednisolone and ADT (STAMPEDE study)
• Ved behandling af metastatisk gastrisk kræft indgives Docetaxel Zentiva i kombination med cisplatin og 5-fluoruracil.
- For the treatment of metastatic gastric cancer, Docetaxel Zentiva is administered in combination with cisplatin and 5-fluorouracil.
Den anbefalede doxetaxel-dosis til adjuverende behandling af operabel lymfeknude-positiv og lymfeknude-negativ brystkræft er 75 mg/m hver 3. uge i 6 perioder, administreret 1 time efter doxorubicin 50 mg/m2 og cyclophosphamid 500 mg/m2 (TAC-regime) (se også: Dosisjustering under behandling).
In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of docetaxel is 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment).
På basis af farmakokinetiske data med docetaxel givet som enkeltstof ved en dosis på 100 mg/m2, er den anbefalede dosis docetaxel 75 mg/m til patienter, som både har forhøjelse af transaminase (ALAT og/eller ASAT) på mere end 1,5 gange den øvre normalværdi og af basisk fosfatase på mere end 2,5 gange den øvre normalværdi ( se pkt.
Based on pharmacokinetic data with docetaxel at 100 mg/m² as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and alkaline phosphatase greater than 2.5 times the ULN, the recommended dose of docetaxel is 75 mg/m2 (see sections 4.4 and 5.2).
Brug af anden medicin sammen med Docetaxel Zentiva
Other medicines and Docetaxel Zentiva
Hjælpestoffer som behandleren skal være opmærksom på: Hvert hætteglas med koncentrat indeholder 0,5 ml ethanol, vandfri (395 mg).
Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).
Bemærk, at dette sandsynligvis er underestimeret, da docetaxel alene ved en dosis på 100 mg/m er kendt for at resultere i neutropeni hos
Note that this is likely to be an underestimate since docetaxel alone at a dose of 100 mg/m2 is known to result in neutropenia in 97% of patients, 76% grade 4, based on nadir blood counts.
Docetaxel Zentiva er ordineret af din læge til behandling af bryst- eller specielle former for lungekræft (ikke-småcellet lungekræft), prostata kræft, gastrisk kræft eller hoved- og hals-kræft:
Docetaxel Zentiva has been prescribed by your doctor for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer: - For the treatment of advanced breast cancer, Docetaxel Zentiva could be administered either alone or in combination with doxorubicin, or trastuzumab, or capecitabine.
Fejlfri overlevelse: tiden fra randomiseringen til første bevis for mindst et af: biokemisk svigt (defineret som en stigning i PSA på 50 % over inden-24-ugers nadir og over 4 ng/ml og bekræftet ved omtest eller behandling); progression enten lokalt, i lymfeknuder eller i fjerne metastaser, skeletrelateret begivenhed; eller død af prostatakræft.
95% CI p-valuea a p-value calculated from the likelihood ratio test and adjusted for all stratification factors (except center and planned hormone therapy) and stratified by trial period b Failure-free survival: time from randomization to first evidence of at least one of: biochemical failure (defined as a rise in PSA of 50% above the within-24-week nadir and above 4 ng/mL and confirmed by retest or treatment); progression either locally, in lymph nodes, or in distant metastases; skeletal-related event; or death from prostate cancer.
95 %CI p-værdi
95% CI p-valuea
Infektion associeret med G4-neutropeni (G3/4:
Infection associated with G4 neutropenia
Sådan skal du bruge Docetaxel Zentiva
How to use Docetaxel Zentiva
Docetaxel Zentiva 160 mg/8 ml koncentrat til infusionsvæske, opløsning kræver INGEN forudgående fortynding med en solvens, men er klar til tilsætning til infusionsvæske.
Docetaxel Zentiva 160 mg/8 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
• Induktions kemoterapi efterfulgt af kemo-stråleterapi (TAX 324) Til den indledende behandling af patienter med lokalt fremskreden pladecellecarcinom i hoved og hals (SCCHN) (ikke muligt af resektere, lav sandsynlighed for kirurgisk helbredelse samt med bevarelse af organer som mål), er den anbefalede dosis docetaxel 75 mg/m som en 1-times intravenøs infusion på dag 1, efterfulgt af cisplatin 100 mg/m administreret som en 30 minutter til 3 timers infusion, efterfulgt af 5-fluoruracil 1000 mg/m som en kontinuerlig infusion fra dag 1 til dag 4.
• Induction chemotherapy followed by chemoradiotherapy (TAX 324) For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m2 as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m2 administered as a 30-minute to 3-hour infusion, followed by 5-fluorouracil 1000 mg/m2/day as a continuous infusion from day 1 to day 4.
• Injicer via en enkelt injektion (et stik) den nødvendige mængde Docetaxel Zentiva koncentrat til infusionsvæske, opløsning i en 250 ml infusionspose eller -flaske indeholdende enten en 5 % glucoseinfusionsvæske eller en 0,9 % natriumchloridinfusionsvæske.
• Then, inject via a single injection (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Total overlevelse (Primær endepunkt) Median overlevelsestid (måneder)
Median overall survival (months)
U kabelovny 130 102 37 Prague 10
102 37 Prague 10
Hver ml koncentrat indeholder 20 mg docetaxel (som trihydrat).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 20 mg docetaxel (as trihydrate).
• Til behandling af hoved- og hals-kræft indgives Docetaxel Zentiva i kombination med cisplatin og 5-fluoruracil.
- For the treatment of head and neck cancer, Docetaxel Zentiva is administered in combination with cisplatin and 5-fluorouracil.
Docetaxel Zentiva 20 mg/1 ml koncentrat til infusionsvæske, opløsning kræver INGEN forudgående fortynding med en solvens, men er klar til tilsætning til infusionsvæske.
Docetaxel Zentiva 20 mg/1 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Udtag aseptisk den ønskede mængde af Docetaxel Zentiva koncentrat til infusionsvæske, opløsning, med en kalibreret sprøjte påsat en 21G-kanyle.
Aseptically withdraw the required amount of Docetaxel Zentiva concentrate for solution for infusion using a calibrated syringe fitted with a 21G needle.
Docetaxel Zentiva 80 mg/4 ml koncentrat til infusionsvæske, opløsning kræver INGEN forudgående fortynding med en solvens, men er klar til tilsætning til infusionsvæske.
Docetaxel Zentiva 80 mg/4 ml concentrate for solution for infusion requires NO prior dilution with a solvent and is ready to add to the infusion solution.
Hjælpestoffer som behandleren skal være opmærksom på: Hvert hætteglas med koncentrat indeholder 2 ml ethanol, vandfri (1,58 g).
Each vial of concentrate contains 2 ml of ethanol anhydrous (1.58 g).
Det skal du vide, før du begynder at bruge Docetaxel Zentiva Sådan skal du bruge Docetaxel Zentiva Bivirkninger
What Docetaxel Zentiva is and what it is used for What you need to know before you use Docetaxel Zentiva How to use Docetaxel Zentiva Possible side effects
Docetaxel Zentiva i kombination med trastuzumab er indiceret til behandling af patienter med metastatisk brystkræft, hvis tumorer overudtrykker HER2, og som ikke tidligere har fået kemoterapi mod metastatisk sygdom.
Docetaxel Zentiva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.
Tabel over bivirkninger ved behandling af metastatisk kastrationsresistent prostatakræft med Docetaxel Zentiva 75 mg/m² i kombination med prednison eller prednisolon:
Tabulated list of adverse reactions in metastatic castration-resistant prostate cancer for Docetaxel Zentiva 75 mg/m² in combination with prednisone or prednisolone
Data fra et multicenter, åbent, randomiseret studium støtter anvendelsen af Docetaxel Zentiva som adjuverende behandling til patienter med operabel, lymfeknude-negativ brystkræft, der er egnede til kemoterapibehandling.
Data from a multi-centre open label randomised trial support the use of Docetaxel Zentiva for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy .
• androgen deprivationsbehandling + docetaxel 75 mg/m² i begyndelsen af androgen deprivationsbehandlingen, administeret hver 3. uge i 6 perioder
• ADT + docetaxel 75 mg/m² given at the beginning of ADT, administered every 3 weeks for 6 cycles
Dette lægemiddel indeholder 50 % vol. ethanol, vandfri (alkohol) dvs. op til 395 mg ethanol, vandfri pr. hætteglas, svarende til 10 ml øl eller 4 ml vin.
This medicinal product contains 50 vol % ethanol anhydrous (alcohol), i.e. up to 395 mg ethanol anhydrous per vial, equivalent to 10 ml of beer or 4 ml wine.
ritonavir, saquinavir, telithromycin og voriconazol) ikke kan undgås, er tæt klinisk overvågning nødvendig, og justering af docetaxeldosis kan være hensigtsmæssig under behandling med potente CYP3A4-hæmmere (se pkt.
If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4).
Docetaxel Zentiva i kombination med cisplatin er indiceret til behandling af patienter med inoperabel lokalt fremskreden eller metastatisk ikke-småcellet lungekræft hos patienter, der ikke tidligere har fået kemoterapi mod denne tilstand.
Docetaxel Zentiva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Docetaxel Zentiva i kombination med capecitabin er indiceret til behandling af patienter med lokal fremskreden eller metastatisk brystkræft efter svigt af cytotoksisk kemoterapi.
Docetaxel Zentiva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
(PF) daglig i 5 dage.
1000 mg/m2 per day for 5 days.
Hjælpestoffer som behandleren skal være opmærksom på: Hvert hætteglas med koncentrat indeholder 4 ml ethanol, vandfri (3,16 g).
Each vial of concentrate contains 4 ml of ethanol anhydrous (3.16 g).
Docetaxel Zentiva koncentrat til infusionsvæske, opløsning er en lys gul til brunliggul opløsning.
What Docetaxel Zentiva looks like and contents of the pack Docetaxel Zentiva concentrate for solution for infusion is a pale yellow to brownish-yellow solution.
Docetaxel Zentiva i kombination med trastuzumab
Docetaxel Zentiva in combination with trastuzumab
• Udtag aseptisk den ønskede mængde Docetaxel Zentiva koncentrat til infusionsvæske, opløsning, med en kalibreret sprøjte påsat en 21G-kanyle.
• Aseptically withdraw the required amount of concentrate for solution for infusion with a calibrated syringe fitted with a 21G needle.